INmune Bio Inc. (INMB)
INmune Bio Statistics
Share Statistics
INmune Bio has 22.93M shares outstanding. The number of shares has increased by 34.42% in one year.
| Shares Outstanding | 22.93M |
| Shares Change (YoY) | 34.42% |
| Shares Change (QoQ) | 19.93% |
| Owned by Institutions (%) | 30.57% |
| Shares Floating | 16.3M |
| Failed to Deliver (FTD) Shares | 42.84K |
| FTD / Avg. Volume | 12.82% |
Short Selling Information
The latest short interest is 6.06M, so 26.71% of the outstanding shares have been sold short.
| Short Interest | 6.06M |
| Short % of Shares Out | 26.71% |
| Short % of Float | 33.28% |
| Short Ratio (days to cover) | 20.24 |
Valuation Ratios
The PE ratio is -2.24 and the forward PE ratio is -4.61. INmune Bio's PEG ratio is -0.09.
| PE Ratio | -2.24 |
| Forward PE | -4.61 |
| PS Ratio | 6733.36 |
| Forward PS | 1.3 |
| PB Ratio | 2.94 |
| P/FCF Ratio | -2.83 |
| PEG Ratio | -0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for INmune Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.14 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.08K |
| Profits Per Employee | $-3.24M |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -22.32% in the last 52 weeks. The beta is 1.88, so INmune Bio's price volatility has been higher than the market average.
| Beta | 1.88 |
| 52-Week Price Change | -22.32% |
| 50-Day Moving Average | 7.98 |
| 200-Day Moving Average | 6.76 |
| Relative Strength Index (RSI) | 56.32 |
| Average Volume (20 Days) | 334.16K |
Income Statement
In the last 12 months, INmune Bio had revenue of 14K and earned -42.08M in profits. Earnings per share was -2.08.
| Revenue | 14K |
| Gross Profit | 14K |
| Operating Income | -42.63M |
| Net Income | -42.08M |
| EBITDA | -42.63M |
| EBIT | -42.63M |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
The company has 20.92M in cash and 384K in debt, giving a net cash position of 20.54M.
| Cash & Cash Equivalents | 20.92M |
| Total Debt | 384K |
| Net Cash | 20.54M |
| Retained Earnings | -163.1M |
| Total Assets | 39.56M |
| Working Capital | 15.44M |
Cash Flow
In the last 12 months, operating cash flow was -33.36M and capital expenditures 0, giving a free cash flow of -33.36M.
| Operating Cash Flow | -33.36M |
| Capital Expenditures | 0 |
| Free Cash Flow | -33.36M |
| FCF Per Share | -1.65 |
Margins
Gross margin is 100%, with operating and profit margins of -304535.71% and -300585.71%.
| Gross Margin | 100% |
| Operating Margin | -304535.71% |
| Pretax Margin | -300585.71% |
| Profit Margin | -300585.71% |
| EBITDA Margin | -304535.71% |
| EBIT Margin | -304535.71% |
| FCF Margin | -238292.86% |
Dividends & Yields
INMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for INMB is $23, which is 178.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 178.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 4.77 |
| Piotroski F-Score | 2 |